Avivagen Inc. (VIVXF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.36: the stock has moved about 64% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAvivagen Inc. (VIVXF) trades at $0.0001. Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and enhance animal growth. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for VIVXF: VIVXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Avivagen Inc. (VIVXF) Healthcare & Pipeline Overview
Avivagen Inc. is a life sciences company specializing in developing and commercializing products for livestock feeds, primarily OxC-beta Livestock, which supports immune function and enhances animal productivity. The company serves markets across North America, Asia, and Latin America, operating within the specialty and generic drug manufacturing sector.
What Is the Investment Thesis for VIVXF?
Avivagen Inc. presents a focused investment opportunity within the animal health sector, driven by its OxC-beta Livestock product. The company's gross margin of 42.6% indicates potential profitability as sales scale. Growth catalysts include expanding distribution networks in key markets such as China and Brazil. However, the company's negative profit margin of -645.9% and reliance on a single core product represent significant risks. The company's small market capitalization and OTC listing add further complexity. Investors should closely monitor the company's ability to achieve profitability and diversify its product line.
Based on FMP financials and quantitative analysis
VIVXF Key Highlights
Gross Margin of 42.6% indicates potential for profitability as sales volume increases.
- Serves markets in the United States, Canada, the Philippines, Taiwan, Thailand, China, Mexico, and Brazil, demonstrating a global presence.
- Offers OxC-beta Livestock, a premix for livestock feeds, targeting the animal health and nutrition market.
- Market Cap of $0.00B indicates a micro-cap company with high growth potential but also higher risk.
- Beta of 0.36 suggests lower volatility compared to the overall market.
Who Are VIVXF's Competitors?
VIVXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| TAK Takeda Pharmaceutical Company Limited | $17.81 | -0.31% | $56.8B | 64 5-pillar |
| TEVA Teva Pharmaceutical Industries Limited | $39.66 | +0.33% | $46.2B | 66 5-pillar |
| HLN Haleon plc | $8.82 | +0.23% | $38.8B | 78 5-pillar |
| ZTS Zoetis Inc. | $71.41 | +2.47% | $29.2B | 87 5-pillar |
| VTRS Viatris Inc. | $17.62 | +0.11% | $20.5B | 32 5-pillar |
| ELAN Elanco Animal Health Incorporated | $22.51 | +1.67% | $11.2B | 33 5-pillar |
| RDY Dr. Reddy's Laboratories Limited | $12.32 | +0.57% | $10.2B | 81 5-pillar |
| LNTH Lantheus Holdings, Inc. | $100.19 | +0.23% | $6.52B | 91 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VIVXF's Key Strengths?
Proprietary OxC-beta Livestock formulation.
- Established presence in multiple geographic markets.
- Focus on immune function and animal health.
- Diversified product line including pet health products.
What Are VIVXF's Weaknesses?
Negative profit margin.
- Small market capitalization.
- Reliance on a single core product.
- Limited financial resources.
What Are the Key Risks for VIVXF?
Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
- Negative profit margin and limited financial resources.
- Competition from larger animal health companies.
- Regulatory changes in key markets.
- Reliance on a single core product.
- Fluctuations in commodity prices affecting feed costs.
What Are VIVXF's Competitive Advantages?
- Proprietary formulations for immune support.
- Established distribution network in key markets.
- Brand recognition for OxC-beta Livestock.
- Focus on a specific niche within the animal health market.
What Does VIVXF Do?
Avivagen Inc., established in 2005 and headquartered in Ottawa, Canada, is a life sciences company dedicated to improving livestock health and productivity through innovative feed solutions. The company's flagship product, OxC-beta Livestock, is a premix designed to be incorporated into livestock feeds, promoting immune function and overall animal well-being. This product is distributed across various regions, including the United States, Canada, the Philippines, Taiwan, Thailand, China, Mexico, and Brazil. Beyond livestock, Avivagen also offers health chews for dogs under the Vivamune brand, along with Dr. Tobias dog chews, and Dr. Tobias Beta blend for the human immune system. These products leverage the company's expertise in developing immune-supporting formulations. The company's focus remains on developing and commercializing products that enhance animal health and productivity, contributing to more sustainable and efficient livestock farming practices. Avivagen operates with a team of 13 employees, managing its operations and distribution network across its target markets.
What Products and Services Does VIVXF Offer?
- Develops and commercializes products for livestock feeds.
- Offers OxC-beta Livestock, a premix for inclusion in livestock feeds.
- Provides solutions that support immune function in animals.
- Aims to enhance animal growth and productivity.
- Offers Vivamune health chews for dogs.
- Markets Dr. Tobias dog chews and Dr. Tobias Beta blend for human immune systems.
How Does VIVXF Make Money?
- Develops and manufactures feed additives and supplements.
- Sells products to feed manufacturers and distributors.
- Generates revenue through product sales in various geographic markets.
- Focuses on livestock health and productivity.
What Industry Does VIVXF Operate In?
Avivagen Inc. operates within the animal health and nutrition industry, a sector driven by increasing demand for protein and growing awareness of animal welfare. The market is characterized by established players offering a range of feed additives and supplements. Avivagen's focus on immune function through its OxC-beta Livestock product positions it within a niche segment of the broader market. The company faces competition from larger, more established companies, requiring a focused market strategy and effective distribution partnerships.
Who Are VIVXF's Key Customers?
- Livestock feed manufacturers.
- Animal distributors.
- Farmers and livestock producers.
- Pet owners (for dog chews).
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
Avivagen Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
Key Financial Metrics
Return on equity for Avivagen Inc. stands at 122.1%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.61 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Avivagen Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Ottawa, CA. The company is led by CEO G. F. Kym Anthony. VIVXF has traded publicly since 2013.
Earnings Track Record
Avivagen Inc. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 17.9% below estimates on average.
VIVXF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
VIVXF Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
VIVXF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for VIVXF.
Price Targets
Wall Street price target analysis for VIVXF.
VIVXF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for VIVXF; grades run from A+ (80-100) to F (below 30).
Leadership: G. F. Kym Anthony
CEO
G. F. Kym Anthony serves as the CEO of Avivagen Inc., leading a team of 13 employees. His background includes extensive experience in managing and growing small to medium-sized enterprises, with a focus on strategic planning and market development. He has a proven track record in the life sciences sector, particularly in bringing innovative products to market. Anthony holds a degree in Business Administration and has completed executive education programs in leadership and innovation.
Track Record: Since assuming the role of CEO, G. F. Kym Anthony has focused on expanding Avivagen's market presence and driving sales growth for OxC-beta Livestock. Key achievements include securing distribution agreements in new geographic regions and overseeing the development of new product formulations. Under his leadership, the company has also strengthened its intellectual property portfolio and implemented cost-saving measures to improve financial performance.
VIVXF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Avivagen Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Investing in OTC Other stocks carries a higher degree of risk compared to stocks listed on major exchanges due to the lack of regulatory oversight and reporting standards.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Potential for price manipulation.
- Lack of regulatory oversight.
- Thin trading volume.
- Higher risk of fraud or mismanagement.
- Verify the company's financial statements.
- Research the background of the management team.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory filings.
- Evaluate the company's intellectual property portfolio.
- Monitor trading volume and price activity.
- Consult with a financial advisor.
- Established presence in multiple geographic markets.
- Proprietary OxC-beta Livestock formulation.
- Focus on animal health and nutrition.
- Management team with experience in the life sciences sector.
What Investors Ask About Avivagen Inc. (VIVXF) — Healthcare
What do analysts say about VIVXF stock?
As of March 16, 2026, there is limited analyst coverage specifically for VIVXF due to its OTC listing and small market capitalization. Key valuation metrics such as the P/E ratio (-0.11) and profit margin (-645.9%) indicate that the company is currently not profitable.
What are the main risks for VIVXF?
The main risks for Avivagen Inc. include its negative profit margin, reliance on a single core product (OxC-beta Livestock), and limited financial resources. Regulatory changes in key markets could also impact the company's ability to sell its products.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- Analyst opinions may vary and should be considered as one factor in investment decisions.
- OTC stocks carry a higher degree of risk compared to stocks listed on major exchanges.